1
|
Shaliman D, Takenobu H, Sugino RP, Ohira M, Kamijo T. The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma. Eur J Cell Biol 2022; 101:151238. [PMID: 35636260 DOI: 10.1016/j.ejcb.2022.151238] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2021] [Revised: 05/10/2022] [Accepted: 05/12/2022] [Indexed: 01/11/2023] Open
Abstract
Epigenetic modifications by polycomb repressive complex (PRC) molecules appear to play a role in the tumorigenesis and aggressiveness of neuroblastoma (NB). Embryonic ectoderm development (EED) is a member of the PRC2 complex that binds to the H3K27me3 mark deposited by EZH2 via propagation on adjacent nucleosomes. We herein investigated the molecular roles of EED in MYCN-amplified NB cells using EED-knockdown (KD) shRNAs, EED-knockout sgRNAs, and the EED small molecule inhibitor EED226. The suppression of EED markedly inhibited NB cell proliferation and flat and soft agar colony formation. A transcriptome analysis using microarrays of EED-KD NB cells indicated the de-repression of cell cycle-regulated and differentiation-related genes. The results of a GSEA analysis suggested that inhibitory cell cycle-regulated gene sets were markedly up-regulated. Furthermore, an epigenetic treatment with the EED inhibitor EED226 and the HDAC inhibitors valproic acid/SAHA effectively suppressed NB cell proliferation and colony formation. This combined epigenetic treatment up-regulated cell cycle-regulated and differentiation-related genes. The ChIP sequencing analysis of histone codes and PRC molecules suggested an epigenetic background for the de-repression of down-regulated genes in MYCN-amplified/PRC2 up-regulated NB.
Collapse
Affiliation(s)
- Dilibaerguli Shaliman
- Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan; Laboratory of Tumor Molecular Biology, Department of Graduate School of Science and Engineering, Saitama University, Saitama, Japan
| | - Hisanori Takenobu
- Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan
| | - Ryuichi P Sugino
- Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan
| | - Miki Ohira
- Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan
| | - Takehiko Kamijo
- Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan; Laboratory of Tumor Molecular Biology, Department of Graduate School of Science and Engineering, Saitama University, Saitama, Japan.
| |
Collapse
|
2
|
Fiume D, Lenci I, Milana M, Manzia TM, Massoud R, Tariciotti L, Russo C, Toti L, Baiocchi L. Serum Levels of Granulocyte-Macrophage-colony-stimulating Factor and Stem-cell Factor During Liver Regeneration after Partial Hepatectomy in Humans. Rev Recent Clin Trials 2020; 15:131-136. [PMID: 31971114 DOI: 10.2174/1574887115666200123113623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Revised: 01/01/2020] [Accepted: 01/03/2020] [Indexed: 02/08/2023]
Abstract
BACKGROUND Multiple biological functions have been recognized regarding Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) and Stem Cell Factor (SCF). AIM To evaluate the serum changes of GM-CSF and SCF in patients undergoing surgical resection for liver tumor, in the regenerative phase after surgery in order to identify the possible relationship with the patient, tumor or surgical variables. METHODS Thirty-two consecutive patients (50% male, median age 66), undergoing hepatic resection of liver neoplasm, were evaluated. The liver tumor was Hepatocellular Carcinoma (HCC) in 44% of cases. Other tumors were cholangiocarcinoma and metastasis. Serum levels of GM-CSF and SCF were assessed at baseline and 2 days, 7 days and 4 weeks after surgery. Personal and clinical patient data were also recorded. The statistical analysis was carried out using t-test for unpaired data or ANOVA (repeated measure) for continuous variables and Fisher test for discrete variables. RESULTS GM-CSF levels remained constant after surgery and were compared to baseline values. SCF levels, on the other hand, increased during the time, after surgery. The evaluation of SCF levels (fold increase) according to surgical, patient and tumor variables evidenced some differences. At day 7 and week 4, SCF levels were statistically increased: i) in patients undergoing a large resection in comparison with others (p<0.05); ii) in patients non-cirrhotic in comparison with cirrhotic ones (p=0.02) and finally; iii) in patients with non-HCC tumor in comparison with HCC ones (p=0.02). CONCLUSION During liver regeneration in humans, SCF serum levels are increased allowing to hypothesize a possible role of this chemokine during tissue growth and remodeling.
Collapse
Affiliation(s)
- Diego Fiume
- Department of Experimental Medicine Tor Vergata Policlinic, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
| | - Ilaria Lenci
- Hepatology Unit, Tor Vergata Policlinic, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
| | - Martina Milana
- Hepatology Unit, Tor Vergata Policlinic, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
| | - Tommaso M Manzia
- Unit of Transplant Surgery, Tor Vergata Policlinic, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
| | - Renato Massoud
- Department of Experimental Medicine Tor Vergata Policlinic, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
| | - Laura Tariciotti
- Unit of Transplant Surgery, Tor Vergata Policlinic, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
| | - Carmelo Russo
- Department of Experimental Medicine Tor Vergata Policlinic, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
| | - Luca Toti
- Hepatology Unit, Tor Vergata Policlinic, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
| | - Leonardo Baiocchi
- Hepatology Unit, Tor Vergata Policlinic, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
| |
Collapse
|
3
|
Xia S, Li XP, Cheng L, Han MT, Zhang MM, Shao QX, Xu HX, Qi L. Fish Oil-Rich Diet Promotes Hematopoiesis and Alters Hematopoietic Niche. Endocrinology 2015; 156:2821-30. [PMID: 26061726 PMCID: PMC4511132 DOI: 10.1210/en.2015-1258] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The self-renewal and differentiation of hematopoietic stem cells (HSCs) in bone marrow are essential to replenish all blood cell types, but how this process is influenced by diet remains largely unclear. Here we show that a diet rich in fish oils promotes self-renewal of HSCs and extramedullary hematopoiesis. Chronic intake of a fish oil-rich diet increases the abundance of HSCs, alters the hematopoietic microenvironment, and, intriguingly, induces the expression of matrix metalloproteinase 12 (MMP12) in the bone marrow. Pointing to a direct effect of fish oil on MMP12 expression, omega-3 polyunsaturated fatty acids induce the expression of MMP12 in a dose-dependent manner in bone marrow cells. Importantly, down-regulation of MMP12 activity using an MMP12-specific inhibitor attenuates diet-induced myelopoiesis in both bone marrow and spleen. Thus, a fish oil-rich diet promotes hematopoiesis in the bone marrow and spleen, in part via the activity of MMP12. Taken together, these data provide new insights into diet-mediated regulation of hematopoiesis.
Collapse
Affiliation(s)
- Sheng Xia
- Department of Immunology (S.X., M.Z., Q.S., H.X., L.Q.) and Institute of Clinic Laboratory Diagnosis (S.X., X.L., L.C., M.H., M.Z., Q.S., H.X.), School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, China; and Division of Nutritional Sciences (S.X., L.Q.), Cornell University, Ithaca, New York 14853
| | - Xiao-ping Li
- Department of Immunology (S.X., M.Z., Q.S., H.X., L.Q.) and Institute of Clinic Laboratory Diagnosis (S.X., X.L., L.C., M.H., M.Z., Q.S., H.X.), School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, China; and Division of Nutritional Sciences (S.X., L.Q.), Cornell University, Ithaca, New York 14853
| | - Lu Cheng
- Department of Immunology (S.X., M.Z., Q.S., H.X., L.Q.) and Institute of Clinic Laboratory Diagnosis (S.X., X.L., L.C., M.H., M.Z., Q.S., H.X.), School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, China; and Division of Nutritional Sciences (S.X., L.Q.), Cornell University, Ithaca, New York 14853
| | - Mu-tian Han
- Department of Immunology (S.X., M.Z., Q.S., H.X., L.Q.) and Institute of Clinic Laboratory Diagnosis (S.X., X.L., L.C., M.H., M.Z., Q.S., H.X.), School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, China; and Division of Nutritional Sciences (S.X., L.Q.), Cornell University, Ithaca, New York 14853
| | - Miao-miao Zhang
- Department of Immunology (S.X., M.Z., Q.S., H.X., L.Q.) and Institute of Clinic Laboratory Diagnosis (S.X., X.L., L.C., M.H., M.Z., Q.S., H.X.), School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, China; and Division of Nutritional Sciences (S.X., L.Q.), Cornell University, Ithaca, New York 14853
| | - Qi-xiang Shao
- Department of Immunology (S.X., M.Z., Q.S., H.X., L.Q.) and Institute of Clinic Laboratory Diagnosis (S.X., X.L., L.C., M.H., M.Z., Q.S., H.X.), School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, China; and Division of Nutritional Sciences (S.X., L.Q.), Cornell University, Ithaca, New York 14853
| | - Hua-xi Xu
- Department of Immunology (S.X., M.Z., Q.S., H.X., L.Q.) and Institute of Clinic Laboratory Diagnosis (S.X., X.L., L.C., M.H., M.Z., Q.S., H.X.), School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, China; and Division of Nutritional Sciences (S.X., L.Q.), Cornell University, Ithaca, New York 14853
| | - Ling Qi
- Department of Immunology (S.X., M.Z., Q.S., H.X., L.Q.) and Institute of Clinic Laboratory Diagnosis (S.X., X.L., L.C., M.H., M.Z., Q.S., H.X.), School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, China; and Division of Nutritional Sciences (S.X., L.Q.), Cornell University, Ithaca, New York 14853
| |
Collapse
|
4
|
Huang W, Zhou W, Saberwal G, Konieczna I, Horvath E, Katsoulidis E, Platanias LC, Eklund EA. Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription. Mol Cell Biol 2010; 30:4575-94. [PMID: 20679491 PMCID: PMC2950519 DOI: 10.1128/mcb.01595-09] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2009] [Revised: 01/11/2010] [Accepted: 07/20/2010] [Indexed: 11/20/2022] Open
Abstract
The interferon consensus sequence binding protein (ICSBP) is an interferon regulatory transcription factor, also referred to as IRF8. ICSBP acts as a suppressor of myeloid leukemia, although few target genes explaining this effect have been identified. In the current studies, we identified the gene encoding growth arrest specific 2 (GAS2) as an ICSBP target gene relevant to leukemia suppression. We find that ICSBP, Tel, and histone deacetylase 3 (HDAC3) bind to a cis element in the GAS2 promoter and repress transcription in myeloid progenitor cells. Gas2 inhibits calpain protease activity, and beta-catenin is a calpain substrate in these cells. Consistent with this, ICSBP decreases beta-catenin protein and activity in a Gas2- and calpain-dependent manner. Conversely, decreased ICSBP expression increases beta-catenin protein and activity by the same mechanism. This is of interest, because decreased ICSBP expression and increased beta-catenin activity are associated with poor prognosis and blast crisis in chronic myeloid leukemia (CML). We find that the expression of Bcr/abl (the CML oncoprotein) increases Gas2 expression in an ICSBP-dependent manner. This results in decreased calpain activity and a consequent increase in beta-catenin activity in Bcr/abl-positive (Bcr/abl(+)) cells. Therefore, these studies have identified a Gas2/calpain-dependent mechanism by which ICSBP influences beta-catenin activity in myeloid leukemia.
Collapse
Affiliation(s)
- Weiqi Huang
- Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, Jesse Brown Veteran's Administration Medical Center, Chicago, Illinois
| | - Wei Zhou
- Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, Jesse Brown Veteran's Administration Medical Center, Chicago, Illinois
| | - Gurveen Saberwal
- Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, Jesse Brown Veteran's Administration Medical Center, Chicago, Illinois
| | - Iwona Konieczna
- Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, Jesse Brown Veteran's Administration Medical Center, Chicago, Illinois
| | - Elizabeth Horvath
- Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, Jesse Brown Veteran's Administration Medical Center, Chicago, Illinois
| | - Efstratios Katsoulidis
- Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, Jesse Brown Veteran's Administration Medical Center, Chicago, Illinois
| | - Leonidas C. Platanias
- Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, Jesse Brown Veteran's Administration Medical Center, Chicago, Illinois
| | - Elizabeth A. Eklund
- Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, Jesse Brown Veteran's Administration Medical Center, Chicago, Illinois
| |
Collapse
|